TY - CHAP
T1 - The Advances of Biomacromolecule-based Nanomedicine in Brain Disease
AU - Weng, Yuhua
AU - Huang, Yuanyu
N1 - Publisher Copyright:
© Springer Nature Singapore Pte Ltd. 2019.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Brain diseases affect a sizable portion of people in the world. Various treatment modalities have been pursued to control, alleviate, or cure these disorders. Biomacromolecules, e.g., antibody, peptide, enzyme, cytokine, nucleic acid, etc., are one kind of important and promising therapeutic regimens that have forced researchers to make great efforts to realize their clinical applications. However, effective and safe systemic delivery of biomacromolecules into the brain faces diverse challenges such as insufficient drug administration, degradation in the blood, first pass clearance, physical brain barriers, off-target accumulation, immune response, and toxicity to normal tissues. Nanotechnology offers advanced strategies to address these problems through rational design and fabrication of biomacromolecule-loaded nanomedicine. In this chapter, we summarized the administration strategies to the brain and design concepts of various biomacromolecular nanomedicines, highlighted their recent advances in preclinical and clinical studies, and discussed the existing challenges and our perspectives on this field.
AB - Brain diseases affect a sizable portion of people in the world. Various treatment modalities have been pursued to control, alleviate, or cure these disorders. Biomacromolecules, e.g., antibody, peptide, enzyme, cytokine, nucleic acid, etc., are one kind of important and promising therapeutic regimens that have forced researchers to make great efforts to realize their clinical applications. However, effective and safe systemic delivery of biomacromolecules into the brain faces diverse challenges such as insufficient drug administration, degradation in the blood, first pass clearance, physical brain barriers, off-target accumulation, immune response, and toxicity to normal tissues. Nanotechnology offers advanced strategies to address these problems through rational design and fabrication of biomacromolecule-loaded nanomedicine. In this chapter, we summarized the administration strategies to the brain and design concepts of various biomacromolecular nanomedicines, highlighted their recent advances in preclinical and clinical studies, and discussed the existing challenges and our perspectives on this field.
KW - Antibody
KW - Biomacromolecule
KW - Enzyme
KW - Nanomedicine
KW - Nucleic acid
KW - Peptide
UR - http://www.scopus.com/inward/record.url?scp=85105904689&partnerID=8YFLogxK
U2 - 10.1007/978-981-13-8731-9_7
DO - 10.1007/978-981-13-8731-9_7
M3 - Chapter
AN - SCOPUS:85105904689
SN - 9789811387302
SP - 181
EP - 208
BT - Nanomedicine in Brain Diseases
PB - Springer Singapore
ER -